Bioymifi

SKU: orb1306582

Description

Bioymifi

Research Area

Cell Biology

Key Properties

• CAS Number: 1420071-30-2
• MW: 494.32
• Purity: 98.00%
• Formula: C₂₂H₁₂BrN₃O₄S
• SMILES: Brc1ccc(cc1)N1C(=N)S\C(=C/c2ccc(o2)-c2ccc3C(=O)NC(=O)c3c2)C1=O
• Target: TNF,Apoptosis
• Solubility: DMSO:7.5 mg/mL (15.17 mM)

Bioactivity

• Target IC50:
  DR5 receptor:1.2 μM(Kd)
• In Vivo:
  METHODS: To investigate the role of DR5 activation in the heart, Bioymifi (5 mg/kg/d) micro-osmotic pump was administered to C57BL/6 mice once daily for two weeks. RESULTS: Administration of Bioymifi resulted in hypertrophy at the level of cardiac organs and cardiomyocytes, but did not affect cardiomyocyte death or cardiac fibrosis.
• In Vitro:
  METHODS: Erythrocytes were treated with Bioymifi (10-100 µM) for 24 h. The hemolytic and bactericidal properties and potential molecular mechanisms of Bioymifi were characterized by flow cytometry. RESULTS: Bioymifi exerted a dose-responsive, calcium-independent hemolytic effect, reduced erythrocyte hemoglobin, significantly increased membrane-bound protein V, Fluo4, and DCF-positive cells, as well as a dual effect on forward and lateral light scatter. METHODS: Neonatal rat ventricular myocytes (nrvm) were treated with Bioymifi (10 µM) for 24 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: The expression of DR5 in Bioymifi-treated nrvm was higher than that of NRVF.
• Cell Research:
  Dose-response curves of bioymifi and A2C2 in T98 g cells are plotted as a function of A2C2 or bioymifi concentration. Human glioblastoma (T98 g) cells are treated with various concentrations of A2C2 or bioymifi alone or in combination with 1 μM Smac mimetic (SM) for 48 h. The corresponding cell survival is normalized to the treatment without A2C2 or bioymifi.(Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, extracellular, Inhibitor, aggregation, cancer, Bioymifi, Apoptosis, cells, caspase-8, DR5, DR5 Activator, domain, TNFR, TNF Receptor, Tumor Necrosis Factor Receptor

Compound Identifiers

PubChem CID

70678419